Multiple Sclerosis (MS) is an immune disorder. It is caused by an immune mediated attack targeting the myelin sheath. The myelin sheath acts as an “insulator” for neurons so that they can communicate properly with each other. At the root of the disease is a pool of immune cells called T-cells, which actively proliferate, cross the blood brain barrier, and attack myelin sheath present around the nerves. Our primary goal then is to interfere with myelin-specific T-cell proliferation. Mesenchymal stem cells (MSCs) have been shown in multiple studies to have the capacity to block this so-called clone like expansion of activated T cells in a way which is different from immune suppressing drugs, which suppress all immune reactions.

  • Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
  • The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
  • Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
  • The bone marrow derived mesenchymal stem cell are collected from Ischial crest under mild local anaesthesia.
  • Since HUCT mesenchymal and aotologous stem cells are not rejected and hencveneed no HLA typing.
  • There is a growing body of evidence showing that mesenchymal stem cells from umbilical cords are very robust.

 

  • Since HUCT mesenchymal stem cells are immune system privileged, cell rejection is not an issue and Human Leukocyte Antigen (HLA) matching is not necessary.
  • The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
  • Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
  • Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
  • No need to collect stem cells through invasive procedures such as liposuction or bone marrow collection
  • There is a growing body of evidence showing that HUCT mesenchymal stem cells are more robust than mesenchymal stem cells from other sources such as fat.

The body’s immune system is unable to recognize umbilical cord-derived mesenchmyal stem cells as foreign and therefore they are not rejected. HUCT stem cells have been administered thousands of times at the Stem Cell Institute and there has never been a single instance rejection (graft vs. host disease). Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat and therefore, they are considered to be more “potent”.

In this next video (just past the 1 minute mark), Arnold Caplan, PhD explains the mechanism by which donor mesenchymal stem cells shield themselves from the recipient’s immune system. Dr. Caplan is the scientist who discovered the mesenchymal stem cell. He is commonly referred to as “the father of the mesenchymal stem cell”.

How are the stem cells administered for MS treatment?

The HUCT stem cells are administered intravenously by a licensed physician. Additional methods may be recommended.

Stem Cell Therapy for Multiple Sclerosis: *Treatment Protocols

Below is an example of a typical 4-day multiple sclerosis treatment *protocol:

  • Medical evaluation, blood testing
  • 6 intravenous injections of human umbilical cord tissue-derived mesenchymal stem cells
  • 4 perilymphatic injections of HUCT mesenchymal stem cells
  • 2 physical therapy sessions
  • 1-month supply of Stem-Kine

*Includes Hilton hotel room with breakfast, WIFI, transportation from and to the airport with VIP airport gate service and expedited customs clearance upon arrival, and transportation between the Hilton and Stem Cell Institute.

All patients receive a one month supply of Stem Kine supplement (only after medical evaluation in Panama)

*After examining each patient’s medical history and other medical information our team of physicians will recommend a specific treatment protocol. Your recommended protocol may differ from the example given above.

What about follow-up after I return home?

We want to help our patients and we care about how you are doing after you return home. Proper follow-up also helps us evaluate treatment efficacy and improve our multiple sclerosis treatment protocol based on observed outcomes.

Therefore, one of our staff will be contacting you after 1 month, 3 months, 4 months, and 1 year after the treatment to follow up on your condition.

May I speak with successfully-treated patients?

Yes, you may. Once you been evaluated and approved for treatment by our medical team, your patient coordinator will be happy to put you in touch with a few.

At present there are no treatments that specifically target the abnormal immune responses in MS. Current approaches, such as interferon, copaxone, or immune suppressants all act in a non‐specific manner, blocking immune responses against the myelin sheath. While these approaches may be useful in reducing the severity of the disease, they do not repair the damage to neurons that has already occurred and therefore they cannot cure multiple sclerosis.

Mesenchymal stem cells (MSCs) have immune modulator properties which may stop the immune cells from attacking the myelin sheath. Mesenchymal stem cells also help in remyelination (re-generation of the myelin sheath) of the affected neurons.

Your Name (required)

Your Email (required)

Phone (required)

Subject

Your Message